Johnson & Johnson (JNJ) Stock Could Be A Bargain On Cash Flow, Fully Priced On Earnings

Johnson & Johnson stock has delivered a strong 5 year run, yet the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful undervaluation while market based multiples lean the other way. That split leaves investors weighing a stock that has already produced solid long term gains against models that do not fully agree on where value now sits.

• Over the past 5 years, Johnson & Johnson has returned 85.7%, which puts current buyers in the position of paying up after a substantial long term climb.
• Expectations around the drug pipeline in areas such as neuropsychiatry and pulmonary arterial hypertension can support the cash flow outlook. However, any setback in clinical data or competitive pressure on key therapies may quickly change how durable those future cash flows look.
• With a value score of 3 out of 6, the broader checks show a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Johnson & Johnson's current price already reflects those future cash flows or if the intrinsic value estimate still leaves room for upside in the long run.

Spot 49 high quality undervalued stocks that, like Johnson & Johnson, have solid long term returns yet still show potential mispricing when cash flow models and market multiples disagree.

Is Johnson & Johnson a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model values Johnson & Johnson by projecting what its future cash generation could be worth in today’s dollars. On the numbers given, the business produced about $21.7b of free cash flow over the last twelve months, and the forecast assumes that cash flow keeps growing rather than shrinking. On those projections, the DCF points to an intrinsic value of about $364 per share in $ terms.

That estimate sits meaningfully above the current share price, implying the stock screens as roughly 26.7% undervalued on this cash flow view. Johnson & Johnson’s work in neuropsychiatry and pulmonary arterial hypertension, highlighted in recent trial updates and conference data, may help explain why the market is assigning some premium already. However, the model still indicates more value than the price reflects.

On this Discounted Cash Flow view, Johnson & Johnson appears undervalued relative to the cash it is projected to generate.

Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 26.7%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Johnson & Johnson.

Has Johnson & Johnson Run Too Far on Earnings?

The P/E ratio works well for Johnson & Johnson because earnings power sits at the center of how investors weigh large pharmaceutical groups. On this metric, the stock trades on about 30.6x earnings. That is not only below the peer average of 50.7x, it is also well above the broader pharmaceuticals industry average of roughly 16.2x.

Put simply, the market is paying a clear premium to the typical pharmaceuticals group for Johnson & Johnson’s earnings stream, even if the multiple comes in lower than some peers. For anyone weighing the DCF signal against market based ratios, this P/E level points to Johnson & Johnson looking overvalued on earnings compared with the sector baseline.

On the P/E yardstick, the stock currently screens as overvalued versus the wider pharmaceuticals industry.

See what the numbers say about this price — find out in our valuation breakdown.

The Johnson & Johnson Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Johnson & Johnson pick up where this valuation puzzle leaves off. They translate the implied expectations behind both the DCF and the P/E multiples into clear statements about the future so you can see what kind of growth, margins and earnings path would need to hold for Johnson & Johnson's stock to be worth much more or much less than it is today, and then track whether reality matches those assumptions on the Community page.

Community views on Johnson & Johnson pull in opposite directions, with one side focused on new medicines and MedTech momentum while the other worries the price already reflects a lot of that story.

Bull case: roughly fairly valued

"Recent acquisitions, such as Intra-Cellular Therapies, are expected to contribute substantial revenue streams, with products like CAPLYTA potentially reaching over $5 billion in peak sales, positively affecting the company’s revenue and EPS in the future…"

Read the full Bull Case to see why Johnson & Johnson could be undervalued

Bear case: 8% overvalued

"At approximately 22 times earnings, JNJ trades near sector averages but commands a modest premium for stability, balance sheet strength, and consistent free cash flow…"

Read the full Bear Case to see why Johnson & Johnson could be overvalued

Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!

The Bottom Line

For Johnson & Johnson, the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful undervaluation, while the P/E view flags the shares as overvalued relative to the wider pharmaceuticals group. That gap reflects different priorities, with the DCF leaning on long term cash generation and the multiples view anchored in how much investors are willing to pay today for those earnings. With broader checks landing in mixed territory, the key question is whether future cash flows from areas like neuropsychiatry and pulmonary arterial hypertension ultimately justify the current premium, or whether the current discount in the intrinsic value estimate proves to be a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com